Current Challenges in Liquid Biopsies

Maik M. Pruess, PhD
Sr. Field Application Scientist

The liquid biopsy has the potential to change cancer research and clinical care through a variety of applications, from early detection and monitoring, to detection of drug resistance and minimal residual disease. However, implementation of the liquid biopsy across research and clinical testing applications is still met with challenges. This video surveys those challenges; from circulating tumor DNA (ctDNA) isolation and quantification, to variable ctDNA shedding rates based on tumor type and stage, to the number of genomic equivalents as it relates to fragment detection and assay performance, and finally, sequencing error suppression.

Please accept preferences, statistics, marketing cookies to watch this video.